Cart
sales@molnova.com
TAS6417
CAS No. 1661854-97-2
TAS6417( —— )
Catalog No. M23746 CAS No. 1661854-97-2
TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 215 | In Stock |
|
| 2MG | 120 | In Stock |
|
| 5MG | 188 | In Stock |
|
| 10MG | 312 | In Stock |
|
| 25MG | 629 | In Stock |
|
| 50MG | 821 | In Stock |
|
| 100MG | 1107 | In Stock |
|
| 200MG | 1516 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAS6417
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
-
DescriptionTAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).
-
In VitroApoptosis Analysis Cell Line:PC-9, H1975, BID007, BID019, BEAS-2B cells.Concentration:0-10 μM.Incubation Time:24-48 h.Result:Led to apoptosis via inhibition of mutant EGFR.
-
In VivoAnimal Model:Mice implanted with NCI-H1975 EGFR D770_N771insSVD xenografts.Dosage:50 and 100 mg/kg.Administration:Orally once daily for 14 days.Result:Showed marked tumor growth inhibition with treatment/control (T/C) ratios of 51% and 19%, respectively.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1661854-97-2
-
Formula Weight396.44
-
Molecular FormulaC23H20N6O
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (315.31 mM)
-
SMILESCC1=C[C@@H](CN2C1=C(C3=C(N=CN=C32)N)C4=CC5=CC=CC=C5N=C4)NC(=O)C=C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
molnova catalog
related products
-
CDK8-IN-13
CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.
-
Pivanex
Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
-
AP-III-a4 hydrochlor...
AP-III-a4 (ENOblock) hydrochloride is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 hydrochloride can be used for the research of cancer and diabetic.
